Natural History of Dilated Cardiomyopathy Due to Ic.77TC /I in Emerin Protein

• Published in: Journal of clinical medicine Vol. 13; no. 3
• Main Authors: Báez-Ferrer, Néstor, Díaz-Flores-Estévez, Felícitas, Pérez-Cejas, Antonia, Avanzas, Pablo, Lorca, Rebeca, Abreu-González, Pedro, Domínguez-Rodríguez, Alberto
• Format: Journal Article
• Language: English
• Published: MDPI AG 01-01-2024
• Subjects: Cardiomyopathy, Dilated; Care and treatment; Complications and side effects; Diagnosis; Heart; Heart diseases; Heart failure; Patient outcomes; Transplantation; Spain
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13030660

(1) Introduction: Dilated cardiomyopathy (DCM) mainly affects young individuals and is the main indication of heart transplantation. The variant c.77T>C (p.Val26Ala) of the gene coding for emerin (EMD) in chromosome Xq28 has been catalogued as a pathogenic variant for the development of DCM, exhibiting an X-linked inheritance pattern. (2) Methods: A retrospective study was conducted covering the period 2015–2023 in patients with DCM of genetic origin. The primary endpoint was patient age at onset of the first composite major cardiac event, in the form of a first episode of heart failure, malignant ventricular arrhythmia, or end-stage heart failure, according to the presence of truncating variant in titin gene (TTNtv) versus the p.Val26Ala mutation in the EMD protein. (3) Results: A total of 31 and 22 patients were included in the EMD group and TTNtv group, respectively. The primary endpoint was significantly higher in the EMD group, with a hazard ratio of 4.16 (95% confidence interval: 1.83–9.46; p = 0.001). At 55 years of age, all the patients in the EMD group had already presented heart failure, nine presented malignant ventricular arrhythmia (29%), and 13 required heart transplantation (42%). (4) Conclusions: DCM secondary to the c.77T>C (p.Val26Ala) mutation in the EMD gene is associated to an increased risk of major cardiac events compared to patients with DCM due to TTNtv, with a large proportion of transplanted patients in the fifth decade of life.